Silver Book Fact

It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.

Tapp, Robyn J., Jonathan E. Shaw, C. Alex Harper, Mazimilian P. de Courten, Beverley Balkau, Daniel J. McCarty, Hugh R. Taylor, Timothy A. Welborn, Paul Z. Zimmet; on behalf of the AusDiab Study Group. The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population. Diabetes Care. 2003; 26(6): 1731-1737

Reference

Title
The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population
Publication
Diabetes Care
Publication Date
2003
Authors
Tapp, Robyn J., Jonathan E. Shaw, C. Alex Harper, Mazimilian P. de Courten, Beverley Balkau, Daniel J. McCarty, Hugh R. Taylor, Timothy A. Welborn, Paul Z. Zimmet; on behalf of the AusDiab Study Group.
Volume & Issue
Volume 26, Issue 6
Pages
1731-1737

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…  
  • Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient–…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.  
  • Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).